Substance / Medication

Adenosine

Overview

Active Ingredient
adenosine
RxNorm CUI
296

Indications

Adenosine Injection, USP is indicated for the following: Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. DOSAGE AND ADMINISTRATION It is important to be sure the adenosine solution actually reaches the systemic circulation (see). Adenosine does

Labeler: ProPharma DistributionUpdated: 2026-01-20T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Adenosine injection is contraindicated in: Second- or third-degree A-V block (except in patients with a functioning artificial pacemaker). Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker). Known hypersensitivity t

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

7
Total Trials
4
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Adenosine-assisted embolization of cerebral arteriovenous malformations: a systematic review and meta-analysis.
Bocanegra-Becerra Jhon E, Andreão Filipi Fim, Acha Sánchez José Luis et al. · J Neurointerv Surg · 2025
PMID: 38937084Meta-Analysis
Mechanistic role of quercetin as inhibitor for adenosine deaminase enzyme in rheumatoid arthritis: systematic review.
Atta Amira, Salem Maha M, El-Said Karim Samy et al. · Cell Mol Biol Lett · 2024
PMID: 38225555Meta-AnalysisFull text (PMC)
Performance of adenosine deaminase in synovial fluid for the diagnosis of tuberculous arthritis: A systematic review and meta-analysis.
Cortes-Quiroz Juan Carlos, Bernal Jose, Rosas Jose et al. · Reumatol Clin (Engl Ed) · 2024
PMID: 38494302Meta-Analysis
Efficacy and safety of adenosine, rapid ventricular pacing and hypothermia in cerebral aneurysms clipping: a systematic review and meta-analysis.
Nager Gabriela Borges, Pontes Julia Pereira Muniz, Udoma-Udofa Ofonime Chantal et al. · Neurosurg Rev · 2024
PMID: 38730072Meta-Analysis
The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
Zou Renrui, Liu Yaqian, Qiu Sangsang et al. · Cancer Biomark · 2023
PMID: 38007640Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Adenosine (substance)
SNOMED CT
35431001
UMLS CUI
C0001443
RxNorm CUI
296
Labeler
ProPharma Distribution

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.